GET DAILY SIGNALSImmunocore Holdings (IMCR): What to Expect from Q3 2026 Results
Key Takeaways
- Immunocore Holdings is expected to report its third quarter (Q3) 2026 results in the first half of November, with Wall Street consensus pointing to a modest net loss per share.
- Earnings per share (EPS) estimates cluster around a loss of $0.10 to $0.17, while revenue forecasts range from roughly $113 million to $153 million, reflecting variance across data providers.
- In the prior quarter (Q2 2026), the company posted revenue of $115.9 million, up 18% year over year, but that figure included a one-time U.S. wholesaler inventory build.
- Management has flagged roughly $120 million in second-half sales rebates tied to a French pricing agreement, a key factor to watch on the income statement.
- Beyond the numbers, investors are focused on KIMMTRAK net sales growth and clinical catalysts, including top-line data from the TEBE-AM Phase 3 trial expected as early as late 2026.
- For more detail on Immunocore's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available on Tickeron.
- To discover automated trading ideas across the market, explore Trending AI Robots.
Why This Earnings Report Matters
Immunocore Holdings is a commercial-stage biotechnology company whose lead product, KIMMTRAK (tebentafusp), is approved for metastatic uveal melanoma (mUM), a rare eye cancer, in roughly 39 countries. Because KIMMTRAK generates essentially all of the company's revenue, each quarterly report serves as a direct read on commercial execution, pricing dynamics, and market penetration. The third quarter carries added weight this year: management warned that a U.S. wholesaler inventory build in Q2 would unwind and that significant European rebates would pressure the second half. With the stock having declined following its August report, this earnings release will test whether underlying demand momentum can offset those headwinds and reassure investors about the company's path toward sustained profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Are Expecting
Analyst expectations for Immunocore's Q3 2026 report vary meaningfully across data providers. Consensus EPS estimates range from a loss of roughly $0.10 to $0.17 per share, while revenue forecasts span approximately $113 million to $153 million. For context, the company reported $103.7 million in revenue in the same quarter a year earlier and $115.9 million in Q2 2026, when EPS came in at a loss of $0.02.
Several factors make this quarter difficult to model. First, management disclosed that Q2 included about $6 million in U.S. wholesaler inventory stocking, which is expected to create a sales headwind in Q3. Second, the company anticipates roughly $120 million in sales-related rebates during the second half of 2026, driven in part by a French pricing agreement. Third, KIMMTRAK penetration in major markets now exceeds 70%, meaning sequential growth is naturally moderating. Investors will therefore pay close attention to net product revenue, gross-to-net adjustments, operating expenses, and cash balance, which stood at roughly $880 million at mid-2026. From what I see, the AI Daily Buy/Sell Signals can help flag shifts in sentiment around these variables.
Market Reaction and Investor Sentiment
Sentiment heading into the report is cautious. Immunocore shares posted a negative post-earnings drift following the August release, when a slight EPS miss and the disclosure of upcoming rebate pressure weighed on the stock. Since then, analysts have issued mixed revisions: HC Wainwright raised its Q3 EPS estimate while maintaining a Buy rating, while others trimmed price targets, citing competitive threats and moderating growth in the core KIMMTRAK franchise. The market's key concern is not the top line alone but the trajectory of net sales after accounting for rebates and inventory normalization. A print that shows stable or improving net product revenue, combined with clearer commentary on rebate timing, could ease pressure, whereas any sign of softer underlying demand would likely extend the cautious tone.
Forward Outlook and Key Factors to Monitor
Following the report, investors should track several forward-looking items. The first is the shape of KIMMTRAK's growth curve. With penetration above 70% in major markets, the company is shifting its growth story toward label expansion rather than same-market gains. Top-line overall survival data from the TEBE-AM Phase 3 registrational trial in previously treated advanced cutaneous melanoma, which completed enrollment of 540 patients, is expected as early as late 2026 and represents a major potential catalyst.
The second area to watch is the financial impact of rebates. Management's guidance of roughly $120 million in second-half rebates could compress reported revenue growth even if underlying patient demand is healthy. Clarity on the timing and size of these items will help investors separate accounting noise from real commercial momentum.
Third, the broader pipeline deserves attention. The PRISM-MEL-301 Phase 3 trial of brenetafusp in first-line cutaneous melanoma and the ATOM adjuvant uveal melanoma study are progressing, while the company has also expanded into autoimmune disease with a Phase 1 program in type 1 diabetes. Finally, the cash position of approximately $880 million provides runway, but operating cash flow turned negative in early 2026, so investors should monitor expense discipline alongside clinical investment. None of these factors point to a single outcome, and the report will be best read as a progress update on both commercial execution and pipeline timelines. One thing that stands out is how the AI Trend Prediction Engine can provide additional context on long-term momentum here.
Tools That Help Me Stay on Top of Biotech Names
I often turn to Tickeron’s AI Screener when preparing for earnings like this one. It lets me quickly filter for similar biotech names by fundamentals, technical patterns, and AI-driven signals, which helps put Immunocore’s setup in perspective without spending hours on manual research. The platform’s customizable filters have become a regular part of my process for spotting comparable opportunities ahead of key reports.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IMCR in +4.25% Uptrend, growing for three consecutive days on October 28, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IMCR advanced for three days, in 219 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMCR's RSI Oscillator exited the oversold zone, 19 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMCR as a result. In 58 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for IMCR turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
IMCR moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for IMCR moved below the 200-day moving average on November 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
IMCR broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMCR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.802) is normal, around the industry mean (3.482). IMCR has a moderately low P/E Ratio (-86.083) as compared to the industry average of (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.791) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. IMCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement